NovAliX
Illkirch
About NovAliX
NovAliX is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing. With proprietary SPR technology, X-ray protein crystallography, supramolecular mass spectrometry and chemistry, NovAliX offers comprehensive integrated services for small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $2.4M
- Last round: Corporate Round (Aug 2024)
- Website: novalix.com
- Phone: +33 0 368 330 200
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/novalix-9687 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.